MCID: BRS044
MIFTS: 59

Breast Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 29 6 15 17 71
Mammary Adenocarcinoma 12 71
Adenocarcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3458
NCIt 49 C5214
UMLS 71 C0858252 C3669246

Summaries for Breast Adenocarcinoma

Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to mammary paget's disease and inflammatory breast carcinoma. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Zoledronic Acid and Propofol have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 33.6 TNFSF11 ESR1 ERBB2 EGFR
2 inflammatory breast carcinoma 33.1 ESR1 ERBB2 EGFR
3 oncocytic breast carcinoma 33.0 ESR1 ERBB2
4 adenocarcinoma 32.7 TP53 RHOA PIK3CA MYC MMP9 KRAS
5 breast cancer 31.5 TP53 TNFSF11 SLC22A18 RHOA RB1CC1 PIK3CA
6 glioblastoma multiforme 31.5 TP53 RHOA PIK3CA MYC MTOR MMP9
7 leukemia 31.4 TP53 MYC KRAS ERBB3 ERBB2 BAX
8 sarcoma 31.3 TP53 PIK3CA MYC MTOR KRAS CYCS
9 ductal carcinoma in situ 31.3 TP53 PIK3CA MYC MMP9 ESR1 ERBB3
10 suppression of tumorigenicity 12 31.3 TP53 PIK3CA MYC MTOR MMP9 KRAS
11 in situ carcinoma 31.3 TP53 PIK3CA MYC ESR1 ERBB2 EGFR
12 breast disease 31.3 TP53 ESR1 ERBB2 EGF BAX
13 prostatic hypertrophy 31.2 ESR1 EGFR EGF
14 ovarian cancer 31.2 TP53 RHOA PIK3CA MYC MTOR MMP9
15 squamous cell carcinoma 31.2 TP53 RHOA PIK3CA MYC MMP9 H19
16 cystadenocarcinoma 31.1 TP53 PIK3CA ERBB2 AKT1
17 osteogenic sarcoma 31.1 TP53 TNFSF11 MYC MMP9 H19 EGF
18 ovarian cystadenocarcinoma 31.1 TP53 PIK3CA MYC KRAS ERBB2 EGFR
19 gastric adenocarcinoma 31.1 TP53 RHOA PIK3CA MYC MTOR MMP9
20 pancreatic cancer 31.1 TP53 RHOA PIK3CA MYC MTOR MMP9
21 lung cancer susceptibility 3 31.1 TP53 PIK3CA MYC MTOR MMP9 KRAS
22 glioma 31.1 TP53 PIK3CA MMP9 H19 ERBB2 EGFR
23 melanoma 31.1 TP53 PIK3CA MYC MTOR KRAS H19
24 comedo carcinoma 31.1 TP53 ESR1 ERBB2
25 teratoma 31.1 TP53 KRAS H19 ESR1 AKT1
26 bone cancer 31.1 TP53 TNFSF11 MMP9 ESR1 EGFR CYCS
27 oral squamous cell carcinoma 31.0 TP53 MYC MMP9 H19 EGFR AKT1
28 polycystic kidney disease 31.0 MYC MTOR EGFR EGF AKT1
29 estrogen-receptor positive breast cancer 31.0 TP53 PIK3CA MYC MTOR ESR1 ERBB3
30 renal cell carcinoma, nonpapillary 31.0 TP53 RHOA PIK3CA MTOR MMP9 H19
31 cholangiocarcinoma 31.0 TP53 PIK3CA MTOR MMP9 KRAS H19
32 colon adenocarcinoma 31.0 TP53 PIK3CA MYC KRAS ERBB2 EGFR
33 leukemia, acute myeloid 31.0 TP53 PIK3CA MYC MTOR MMP9 KRAS
34 hepatocellular carcinoma 31.0 TP53 RHOA PIK3CA MYC MTOR MMP9
35 papilloma 30.9 TP53 KRAS ESR1 EGFR
36 medulloblastoma 30.9 TP53 PIK3CA MYC MTOR MMP9 H19
37 rhabdomyosarcoma 30.9 TP53 SLC22A18 MYC MTOR KRAS H19
38 apocrine adenocarcinoma 30.9 TP53 ESR1 ERBB2 EGFR
39 gastrointestinal stromal tumor 30.9 TP53 MMP9 KRAS ERBB2 EGFR CASP8
40 colorectal adenocarcinoma 30.9 TP53 MYC MMP9 KRAS ERBB2 EGFR
41 neuroblastoma 30.9 TP53 RHOA PIK3CA MYC MTOR MMP9
42 cervical squamous cell carcinoma 30.9 TP53 PIK3CA MYC KRAS EGFR AKT1
43 meningioma, familial 30.9 TP53 PIK3CA MYC ESR1 ERBB2 EGFR
44 intrahepatic cholangiocarcinoma 30.9 TP53 MMP9 KRAS ERBB2 EGFR
45 lung benign neoplasm 30.9 TP53 KRAS EGFR
46 breast ductal carcinoma 30.9 TP53 MMP9 ESR1 ERBB2 EGFR
47 lung squamous cell carcinoma 30.9 TP53 PIK3CA MTOR KRAS EGFR AKT1
48 female breast cancer 30.9 TP53 ESR1 ERBB2 EGFR
49 small cell carcinoma 30.9 TP53 KRAS EGFR
50 keratosis, seborrheic 30.9 TP53 PIK3CA MTOR

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 44)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.74 KRAS PIK3CA EGFR MTOR
2 Decreased viability GR00055-A-2 10.74 KRAS PIK3CA EGFR MTOR
3 Decreased viability GR00055-A-3 10.74 KRAS
4 Decreased viability GR00106-A-0 10.74 ERBB3 KRAS
5 Decreased viability GR00221-A-1 10.74 AKT1 ESR1 KRAS PIK3CA EGFR MTOR
6 Decreased viability GR00221-A-2 10.74 AKT1 ERBB3 ESR1 KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.74 AKT1 MYC ERBB2
8 Decreased viability GR00221-A-4 10.74 AKT1 ERBB3 ESR1 PIK3CA EGFR MTOR
9 Decreased viability GR00249-S 10.74 AKT1 MYC
10 Decreased viability GR00301-A 10.74 ERBB3 KRAS
11 Decreased viability GR00342-S-1 10.74 MTOR
12 Decreased viability GR00342-S-2 10.74 MTOR
13 Decreased viability GR00381-A-1 10.74 KRAS
14 Decreased viability GR00386-A-1 10.74 ESR1
15 Decreased viability GR00402-S-2 10.74 ESR1 PIK3CA MYC
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.65 MTOR
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.65 ERBB3 PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.65 CASP8
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.65 ERBB2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.65 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.65 AKT1 ERBB3 MTOR PIK3CA RHOA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.65 ERBB2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.65 RHOA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.65 PIK3CA
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.65 MTOR MYC
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.65 AKT1 PIK3CA
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.65 PIK3CA
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 10.65 ERBB3
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-2 10.65 CASP8
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 10.65 RHOA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.65 ERBB3 PIK3CA
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.65 AKT1 MTOR PIK3CA
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 10.65 RHOA
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.65 PIK3CA
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.65 AKT1
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.65 ERBB3 MTOR PIK3CA
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.65 CASP8
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.65 MTOR MYC
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.65 AKT1
40 Decreased cell migration GR00055-A-1 9.8 AKT1
41 Decreased cell migration GR00055-A-3 9.8 EGFR MTOR PIK3CA
42 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
43 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
44 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 BAX CASP8 CYCS EGFR ERBB2
2 growth/size/body region MP:0005378 10.51 AKT1 BAX CASP8 CYCS EGF EGFR
3 immune system MP:0005387 10.49 AKT1 BAX CASP8 CYCS EGF EGFR
4 behavior/neurological MP:0005386 10.47 AKT1 BAX CYCS ERBB2 ERBB3 ESR1
5 cardiovascular system MP:0005385 10.47 AKT1 CASP8 CYCS EGFR ERBB2 ERBB3
6 endocrine/exocrine gland MP:0005379 10.47 AKT1 BAX CASP8 CYCS EGF EGFR
7 homeostasis/metabolism MP:0005376 10.47 AKT1 BAX CASP8 EGFR ERBB2 ERBB3
8 mortality/aging MP:0010768 10.44 AKT1 BAX CASP8 CYCS EGFR ERBB2
9 hematopoietic system MP:0005397 10.42 AKT1 BAX CASP8 CYCS EGFR ESR1
10 embryo MP:0005380 10.41 AKT1 CASP8 CYCS EGFR ERBB2 ERBB3
11 integument MP:0010771 10.39 AKT1 CASP8 EGF EGFR ERBB2 ERBB3
12 muscle MP:0005369 10.37 AKT1 BAX CASP8 EGFR ERBB2 ERBB3
13 nervous system MP:0003631 10.36 AKT1 BAX CASP8 CYCS EGFR ERBB2
14 digestive/alimentary MP:0005381 10.3 EGF EGFR ERBB2 ERBB3 ESR1 KRAS
15 neoplasm MP:0002006 10.29 AKT1 BAX CASP8 EGFR ERBB2 ERBB3
16 normal MP:0002873 10.22 AKT1 EGF EGFR ERBB2 ERBB3 ESR1
17 limbs/digits/tail MP:0005371 10.19 BAX EGFR ERBB2 ESR1 KRAS MMP9
18 adipose tissue MP:0005375 10.18 AKT1 EGFR ESR1 MTOR MYC PIK3CA
19 craniofacial MP:0005382 10.16 CYCS EGFR ERBB2 KRAS MYC TNFSF11
20 liver/biliary system MP:0005370 10.13 AKT1 CASP8 EGFR ESR1 KRAS MYC
21 no phenotypic analysis MP:0003012 10.09 EGFR ESR1 KRAS MTOR MYC PIK3CA
22 reproductive system MP:0005389 10.03 AKT1 BAX EGF EGFR ERBB2 ESR1
23 renal/urinary system MP:0005367 9.97 BAX CASP8 EGFR ESR1 KRAS MMP9
24 respiratory system MP:0005388 9.93 AKT1 BAX CASP8 EGFR ERBB2 ERBB3
25 pigmentation MP:0001186 9.85 EGFR ERBB3 KRAS MYC RB1CC1 TP53
26 skeleton MP:0005390 9.77 AKT1 BAX CYCS EGFR ERBB2 ESR1
27 vision/eye MP:0005391 9.28 BAX EGF EGFR KRAS MMP9 PIK3CA

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic Acid Approved Phase 3 118072-93-8 68740
2
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
3
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
4
Lapatinib Approved, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
5
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
6
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
9
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
10
Sodium citrate Approved, Investigational Phase 3 68-04-2
11
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
12
Tamoxifen Approved Phase 3 10540-29-1 2733526
13
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
14
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
15
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
16
ramucirumab Approved, Investigational Phase 3 947687-13-0
17
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
18
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
19
Goserelin Approved Phase 3 65807-02-5 5311128 47725
20
Bevacizumab Approved, Investigational Phase 3 216974-75-3
21
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
23
Entinostat Investigational Phase 3 209783-80-2
24 Analgesics, Opioid Phase 3
25 Anesthetics, General Phase 3
26 Hypnotics and Sedatives Phase 3
27 Anesthetics, Intravenous Phase 3
28 Protein Kinase Inhibitors Phase 2, Phase 3
29 Antibodies Phase 3
30 Antibodies, Monoclonal Phase 3
31 Immunoglobulins Phase 3
32 Citrate Phase 3
33 Hormone Antagonists Phase 3
34 Hormones Phase 3
35 Antineoplastic Agents, Hormonal Phase 3
36 Estrogen Antagonists Phase 3
37 Estrogen Receptor Modulators Phase 3
38 Estrogen Receptor Antagonists Phase 3
39 Estrogens Phase 3
40 Aromatase Inhibitors Phase 3
41 Sodium Channel Blockers Phase 3
42 Anti-Arrhythmia Agents Phase 3
43 Anesthetics Phase 3
44 Anesthetics, Local Phase 3
45 Diuretics, Potassium Sparing Phase 3
46 Mitogens Phase 3
47 Antineoplastic Agents, Immunological Phase 3
48 Histone Deacetylase Inhibitors Phase 3
49 Immunoglobulins, Intravenous Phase 3
50 Angiogenesis Inhibitors Phase 3

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
2 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
3 Regional Anesthesia and Breast Cancer Recurrence Completed NCT00418457 Phase 3 General anesthesia and opioids;Regional analgesia and propofol
4 A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer Recruiting NCT03337724 Phase 2, Phase 3 Ipatasertib;Paclitaxel;Placebo
5 A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib and Paclitaxel vs Herceptin and Paclitaxel With Sequential and Synchronous Anthracycline Recruiting NCT03085368 Phase 2, Phase 3 lapatinib/herceptin
6 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Recruiting NCT03199885 Phase 3 Atezolizumab;Paclitaxel
7 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
8 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Active, not recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
9 A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer Active, not recruiting NCT00703326 Phase 3 docetaxel
10 A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer Active, not recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin;Goserelin Acetate
11 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer Active, not recruiting NCT00433511 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
12 Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
13 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
14 Randomised Multicentric Phase III Study Evaluating the Efficacy of Cicaderma vs Standard Management of Each Site in Preventing Radiodermatitis After Adjuvant Post-operative Breast Irradiation in Patients With Non-metastatic Breast Cancer Not yet recruiting NCT04300829 Phase 3 cicaderma + simple hygiene rules
15 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Suspended NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
16 Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes Completed NCT01693549 Phase 2 Cabazitaxel
17 Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer Completed NCT00284752 Phase 2 Abraxane
18 A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer Completed NCT02301988 Phase 2 Ipatasertib;Paclitaxel;Placebo
19 Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients Completed NCT01097642 Phase 2 Cetuximab;Ixabepilone
20 Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis Completed NCT01784393 Phase 2
21 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
22 T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
23 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer Recruiting NCT02530489 Phase 2 Atezolizumab;Nab-paclitaxel
24 Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer Recruiting NCT03106415 Phase 1, Phase 2 Binimetinib
25 A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II) Recruiting NCT02448420 Phase 2 Palbociclib;Trastuzumab;Endocrine therapy;Chemotherapy;Antibody-Drug Conjugates
26 Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy Recruiting NCT04197687 Phase 2
27 A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation Active, not recruiting NCT02282345 Phase 2 Talazoparib
28 A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer Active, not recruiting NCT02067741 Phase 2 CR1447
29 A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer Terminated NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
30 Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
31 A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Adenocarcinoma of the Breast Completed NCT02204046 Phase 1 BIWA 4
32 A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Completed NCT01161186 Phase 1 nab-paclitaxel, gemcitabine, capecitabine
33 A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors Active, not recruiting NCT02453620 Phase 1 Entinostat
34 Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET Suspended NCT03432741 Phase 1 Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
35 Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting Unknown status NCT00959556
36 Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
37 Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity? Unknown status NCT00578760 aspirin;placebo
38 Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma Completed NCT00495924
39 Investigation of Gene Mutations or Changes in Protein Expression,as Biomarkers With Prognostic/Predictive Value, in Patients With Triple-negative and in Patients With HER2+ Breast Cancer Adenocarcinoma,Who Underwent Intensive Adjuvant Chemotherapy Recruiting NCT04365790
40 Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study Recruiting NCT02306538
41 A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy Active, not recruiting NCT03137693

Search NIH Clinical Center for Breast Adenocarcinoma

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 29

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

40
Breast, Lung, Bone, Endothelial, T Cells, Lymph Node, Brain

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 4594)
# Title Authors PMID Year
1
CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype. 6
29446767 2018
2
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
3
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
4
Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. 6
25808193 2015
5
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
6
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
7
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
8
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
9
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
10
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. 6
21793738 2011
11
Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. 6
21063026 2011
12
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
13
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 6
17611497 2007
14
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 6
17332249 2007
15
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 6
15608678 2005
16
Mutation of the PIK3CA gene in ovarian and breast cancer. 6
15520168 2004
17
High frequency of mutations of the PIK3CA gene in human cancers. 6
15016963 2004
18
Truncating mutations of RB1CC1 in human breast cancer. 6
12068296 2002
19
Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. 6
9520460 1998
20
A new mutation of exon 5 of the P53 gene in breast cancer. 6
8364550 1993
21
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. 6
1673792 1991
22
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. 6
3627975 1987
23
Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. 61
32378445 2020
24
A nanotechnology-based new approach in the treatment of breast cancer: Biosynthesized silver nanoparticles using Cuminum cyminum L. seed extract. 61
32470714 2020
25
Assessing the potential of lignin nanoparticles as drug carrier: Synthesis, cytotoxicity and genotoxicity studies. 61
32114178 2020
26
Synthesis of folic acid conjugated photoluminescent carbon quantum dots with ultrahigh quantum yield for targeted cancer cell fluorescence imaging. 61
32070730 2020
27
Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report. 61
32493163 2020
28
Breast Cancer Metastases to the Paranasal Sinuses Mimicking Inflammatory Sinus Disease. 61
32569060 2020
29
In vitro antiproliferative activity of glabridin derivatives and their in silico target identification. 61
30580626 2020
30
Two New Abietane Diterpenoids from Selaginella moellendorffii Hieron. 61
32246527 2020
31
Characterization and Prospective Applications of the Exopolysaccharides Produced by Rhodosporidium babjevae. 61
32373494 2020
32
Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis. 61
32405891 2020
33
Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells. 61
32526242 2020
34
Expression patterns of er-resident selenoproteins in er- stress conditions caused by methylseleninic acid in different human cancer cells. 61
32562739 2020
35
Isolation and characterization of cytotoxic and insulin-releasing components from the venom of the black-necked spitting cobra Naja nigricollis (Elapidae). 61
32550585 2020
36
1,2,4-Triazolin-5-thione derivatives with anticancer activity as CK1γ kinase inhibitors. 61
32279038 2020
37
In vitro Treatment of a Murine Mammary Adenocarcinoma Cell Line with Recombinant Trypanosoma cruzi Calreticulin Promotes Immunogenicity and Phagocytosis. 61
32526557 2020
38
Proapoptotic activity induced by photodynamic reaction with novel cyanine dyes in caspase-3-deficient human breast adenocarcinoma cell lines (MCF/WT and MCF/DX). 61
32330609 2020
39
AcGly-Phe-Asn(OH) and AcGly-Phe-Asn(NH2) tripeptides selectively affect the proliferation rate of MDA-MB 231 and HuDe cells. 61
32277441 2020
40
Raman Spectroscopy: An Exploratory Study to Identify Post-Radiation Cell Survival. 61
32031014 2020
41
Apoptosis-mediated antiproliferation of A549 lung cancer cells mediated by Eugenia aquea leaf compound 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone and its molecular interaction with caspase receptor in molecular docking simulation. 61
32269629 2020
42
Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. 61
32243160 2020
43
Citrus sinensis and Vitis vinifera Protect Cardiomyocytes from Doxorubicin-Induced Oxidative Stress: Evaluation of Onconutraceutical Potential of Vegetable Smoothies. 61
32370308 2020
44
Targeted drug delivery systems: synthesis and in-vitro bioactivity and apoptosis studies of gemcitabine-carbon dots conjugates. 61
32442994 2020
45
Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent. 61
32392545 2020
46
Evaluation of cytotoxic and anticancer effect of Orobanche crenata methanolic extract on cancer cell lines. 61
32367771 2020
47
Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells. 61
32364081 2020
48
Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis). 61
32364082 2020
49
The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain. 61
32054717 2020
50
Heat shock response regulates stimulus-specificity and sensitivity of the pro-inflammatory NF-κB signalling. 61
32448393 2020

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RB1CC1 nsv1067860deletion Pathogenic 3976 8:53536328-53598019 8:52623768-52685459
2 RB1CC1 nsv1067861deletion Pathogenic 3977 8:53537321-53574220 8:52624761-52661660
3 SLC22A18 NM_002555.5(SLC22A18):c.864_865insNC_000011.10:g.2919738_2919848insertion Pathogenic 6976
4 KRAS NM_033360.4(KRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 12580 rs112445441 12:25398281-25398281 12:25245347-25245347
5 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
6 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
7 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
8 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser)SNV Pathogenic/Likely pathogenic 12370 rs28934874 17:7578479-7578479 17:7675161-7675161
9 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu)SNV Pathogenic/Likely pathogenic 13654 rs121913286 3:178936094-178936094 3:179218306-179218306
10 TP53 NM_001126112.2(TP53):c.451C>A (p.Pro151Thr)SNV Likely pathogenic 12369 rs28934874 17:7578479-7578479 17:7675161-7675161
11 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys)SNV Uncertain significance 13983 rs121434592 14:105246551-105246551 14:104780214-104780214

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.35 TP53 RHOA PIK3CA MYC MTOR MMP9
2
Show member pathways
14.21 TP53 TNFSF11 RHOA PIK3CA MYC MTOR
3
Show member pathways
14.02 TP53 RHOA MYC MMP9 KRAS EGFR
4
Show member pathways
14 TP53 TNFSF11 RHOA MYC MTOR KRAS
5
Show member pathways
13.9 TP53 RHOA RB1CC1 MYC MMP9 KRAS
6
Show member pathways
13.87 TP53 TNFSF11 MYC MTOR KRAS ERBB3
7
Show member pathways
13.86 PIK3CA MYC MTOR KRAS ERBB3 ERBB2
8
Show member pathways
13.74 TP53 RHOA PIK3CA MYC MTOR KRAS
9
Show member pathways
13.69 RHOA MTOR KRAS ERBB3 ERBB2 EGFR
10
Show member pathways
13.68 RHOA PIK3CA MMP9 KRAS ERBB3 ERBB2
11
Show member pathways
13.63 TP53 PIK3CA MTOR KRAS ERBB3 ERBB2
12
Show member pathways
13.62 TP53 TNFSF11 RHOA MTOR KRAS ERBB3
13
Show member pathways
13.57 RHOA PIK3CA MYC MMP9 KRAS EGFR
14
Show member pathways
13.57 TP53 TNFSF11 PIK3CA MYC MMP9 KRAS
15
Show member pathways
13.5 TNFSF11 RHOA KRAS ERBB2 EGFR EGF
16
Show member pathways
13.46 RHOA KRAS ERBB3 ERBB2 EGFR EGF
17
Show member pathways
13.46 KRAS ESR1 ERBB3 ERBB2 EGFR EGF
18
Show member pathways
13.44 PIK3CA MTOR KRAS CYCS CASP8 BAX
19
Show member pathways
13.43 TP53 RHOA MYC MTOR KRAS ERBB3
20
Show member pathways
13.38 TP53 RB1CC1 PIK3CA MTOR KRAS CYCS
21
Show member pathways
13.34 TP53 RHOA PIK3CA MTOR ERBB3 ERBB2
22
Show member pathways
13.28 TP53 TNFSF11 RHOA PIK3CA MTOR MMP9
23
Show member pathways
13.27 TP53 PIK3CA MYC MMP9 KRAS EGFR
24
Show member pathways
13.25 TP53 RHOA MTOR KRAS EGFR EGF
25
Show member pathways
13.19 RHOA MTOR KRAS EGFR EGF AKT1
26
Show member pathways
13.16 TP53 PIK3CA MYC MTOR KRAS ERBB3
27
Show member pathways
13.15 TP53 RHOA PIK3CA MYC MTOR KRAS
28
Show member pathways
13.13 PIK3CA MTOR KRAS ERBB3 ERBB2 EGFR
29
Show member pathways
13.1 RHOA PIK3CA KRAS ERBB2 EGFR EGF
30
Show member pathways
13.09 RHOA PIK3CA MTOR KRAS ERBB3 ERBB2
31
Show member pathways
13.03 TP53 PIK3CA MYC CYCS CASP8 BAX
32 13.02 TP53 MYC KRAS ERBB3 ERBB2 EGFR
33 13.01 TP53 PIK3CA MTOR CYCS CASP8 BAX
34
Show member pathways
12.98 TP53 PIK3CA MTOR KRAS ERBB3 ERBB2
35
Show member pathways
12.95 TP53 PIK3CA MYC KRAS CYCS CASP8
36
Show member pathways
12.93 RHOA PIK3CA KRAS EGFR EGF AKT1
37
Show member pathways
12.91 PIK3CA MYC MTOR KRAS AKT1
38
Show member pathways
12.9 TP53 CYCS CASP8 BAX AKT1
39
Show member pathways
12.9 PIK3CA MTOR MMP9 KRAS ESR1 EGFR
40
Show member pathways
12.89 TP53 MYC ESR1 CYCS CASP8 BAX
41
Show member pathways
12.87 TP53 RHOA PIK3CA MTOR KRAS ESR1
42
Show member pathways
12.84 RHOA PIK3CA MTOR KRAS EGFR EGF
43
Show member pathways
12.84 TP53 PIK3CA MYC KRAS ERBB2 EGFR
44
Show member pathways
12.82 KRAS EGFR EGF CYCS CASP8
45
Show member pathways
12.82 RHOA KRAS EGFR EGF AKT1
46
Show member pathways
12.82 TP53 KRAS EGFR EGF AKT1
47
Show member pathways
12.81 PIK3CA MTOR KRAS EGFR AKT1
48
Show member pathways
12.81 RHOA PIK3CA EGFR EGF CYCS BAX
49 12.79 RHOA PIK3CA KRAS EGFR EGF
50
Show member pathways
12.77 TP53 TNFSF11 PIK3CA MYC MTOR KRAS

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.13 TP53 TNFSF11 SLC22A18 RHOA RB1CC1 PIK3CA
2 mitochondrion GO:0005739 9.92 TP53 MYC MTOR KRAS CYCS CASP8
3 receptor complex GO:0043235 9.71 ERBB3 ERBB2 EGFR EGF
4 nuclear envelope GO:0005635 9.67 SLC22A18 MYC MTOR BAX
5 basal plasma membrane GO:0009925 9.33 ERBB3 ERBB2 EGFR
6 protein-containing complex GO:0032991 9.17 TP53 MYC MTOR ESR1 EGFR CASP8
7 ERBB3:ERBB2 complex GO:0038143 8.96 ERBB3 ERBB2

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.19 PIK3CA MTOR ERBB3 ERBB2 EGFR AKT1
2 positive regulation of transcription, DNA-templated GO:0045893 10.17 TP53 MYC ESR1 EGFR EGF AKT1
3 protein phosphorylation GO:0006468 10.17 PIK3CA MTOR ERBB3 ERBB2 EGFR AKT1
4 negative regulation of apoptotic process GO:0043066 10.14 TP53 RB1CC1 MYC MMP9 EGFR AKT1
5 positive regulation of cell proliferation GO:0008284 10.1 MYC KRAS ERBB3 ERBB2 EGFR EGF
6 regulation of apoptotic process GO:0042981 10.03 TP53 ESR1 CASP8 BAX AKT1
7 protein autophosphorylation GO:0046777 10.01 MTOR ERBB2 EGFR AKT1
8 peptidyl-tyrosine phosphorylation GO:0018108 9.98 ERBB3 ERBB2 EGFR EGF
9 cellular response to hypoxia GO:0071456 9.97 TP53 MYC MTOR AKT1
10 MAPK cascade GO:0000165 9.97 MYC KRAS ERBB3 ERBB2 EGFR EGF
11 negative regulation of neuron apoptotic process GO:0043524 9.95 RHOA PIK3CA KRAS ERBB3 BAX
12 cytokine-mediated signaling pathway GO:0019221 9.95 TP53 TNFSF11 PIK3CA MYC MMP9 KRAS
13 response to estradiol GO:0032355 9.93 MYC ESR1 EGFR CASP8
14 cellular response to mechanical stimulus GO:0071260 9.91 EGFR CASP8 AKT1
15 wound healing GO:0042060 9.91 MTOR ERBB3 ERBB2 EGFR
16 liver development GO:0001889 9.91 RB1CC1 PIK3CA KRAS EGFR
17 positive regulation of gene expression GO:0010628 9.91 TP53 TNFSF11 MYC MTOR KRAS ERBB3
18 positive regulation of kinase activity GO:0033674 9.9 ERBB3 ERBB2 EGFR
19 cellular response to growth factor stimulus GO:0071363 9.9 ERBB2 EGFR AKT1
20 cellular response to organic cyclic compound GO:0071407 9.9 MYC CASP8 AKT1
21 cellular response to drug GO:0035690 9.9 TP53 MYC EGFR
22 positive regulation of cell growth GO:0030307 9.9 RHOA ERBB2 EGFR AKT1
23 positive regulation of epithelial cell proliferation GO:0050679 9.89 MYC ERBB2 EGFR
24 glucose metabolic process GO:0006006 9.89 PIK3CA MYC AKT1
25 positive regulation of neuron apoptotic process GO:0043525 9.89 TP53 RHOA BAX
26 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.89 RHOA MYC CYCS
27 positive regulation of translation GO:0045727 9.89 RHOA MYC MTOR ERBB2
28 cellular response to UV GO:0034644 9.88 TP53 MYC BAX
29 positive regulation of fibroblast proliferation GO:0048146 9.88 MYC ESR1 EGFR
30 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.87 RHOA ESR1 CASP8
31 negative regulation of Notch signaling pathway GO:0045746 9.87 EGFR EGF AKT1
32 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 MYC MTOR EGFR AKT1
33 positive regulation of protein phosphorylation GO:0001934 9.87 RB1CC1 MTOR MMP9 KRAS ERBB2 EGFR
34 neuron apoptotic process GO:0051402 9.86 TP53 ERBB3 BAX
35 cellular response to reactive oxygen species GO:0034614 9.85 MMP9 EGFR AKT1
36 cellular response to cadmium ion GO:0071276 9.85 MMP9 EGFR AKT1
37 positive regulation of vasoconstriction GO:0045907 9.83 RHOA EGFR AKT1
38 positive regulation of DNA binding GO:0043388 9.83 MYC MMP9 EGF
39 ERK1 and ERK2 cascade GO:0070371 9.83 TNFSF11 MYC EGF
40 negative regulation of fibroblast proliferation GO:0048147 9.82 TP53 MYC BAX
41 germ cell development GO:0007281 9.82 MTOR BAX AKT1
42 positive regulation of phosphorylation GO:0042327 9.81 TNFSF11 EGFR EGF
43 epidermal growth factor receptor signaling pathway GO:0007173 9.81 PIK3CA EGFR EGF AKT1
44 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.8 TP53 MMP9 BAX
45 response to gamma radiation GO:0010332 9.79 TP53 MYC BAX
46 cellular response to epidermal growth factor stimulus GO:0071364 9.78 MYC ERBB2 EGFR AKT1
47 positive regulation of MAP kinase activity GO:0043406 9.77 TNFSF11 KRAS ERBB2 EGFR EGF
48 mammary gland alveolus development GO:0060749 9.76 TNFSF11 ESR1 EGF
49 phosphatidylinositol 3-kinase signaling GO:0014065 9.76 PIK3CA ERBB3 ERBB2 AKT1
50 negative regulation of macroautophagy GO:0016242 9.75 PIK3CA MTOR AKT1

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.41 TP53 TNFSF11 RHOA RB1CC1 PIK3CA MYC
2 nucleotide binding GO:0000166 10.08 RHOA PIK3CA MTOR KRAS ERBB3 ERBB2
3 kinase activity GO:0016301 9.85 PIK3CA MTOR ERBB3 ERBB2 EGFR AKT1
4 protein-containing complex binding GO:0044877 9.8 MYC MTOR KRAS EGFR CASP8
5 protein kinase binding GO:0019901 9.7 TP53 RHOA RB1CC1 MTOR ESR1 EGFR
6 ubiquitin protein ligase binding GO:0031625 9.65 TP53 SLC22A18 ERBB3 EGFR CASP8
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.61 ERBB3 ERBB2 EGFR
8 identical protein binding GO:0042802 9.36 TP53 TNFSF11 MTOR MMP9 ESR1 ERBB3
9 ErbB-3 class receptor binding GO:0043125 9.32 ERBB3 ERBB2
10 nitric-oxide synthase regulator activity GO:0030235 9.13 ESR1 EGFR AKT1

Sources for Breast Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....